Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02252068 · ClinicalTrials.gov registry record · NA
Study of Treatment for Opioid Dependence and Anxiety Disorders
A NA study of Anxiety Disorders and Opiate Addiction, sponsored by Mclean Hospital.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT02252068: Completed NA study of Anxiety Disorders and Opiate Addiction, sponsored by Mclean Hospital.
NCT02252068 is a NA study of Anxiety Disorders and Opiate Addiction that has completed, run by Mclean Hospital. The registered enrollment target is 37 participants, below the 1,140-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02252068, a NA study of Anxiety Disorders and Opiate Addiction, has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
Anxiety is highly prevalent among individuals with opioid dependence and confers greater risk for continued opioid use and poor treatment outcomes. However, there are currently no efficacious treatments available for co-occurring opioid dependence and anxiety. The ultimate aims of this trial are the development and testing of a novel integrated cognitive behavioral treatment (I-CBT) for co-occurring opioid dependence and anxiety disorders. This clinical trial consists of two phases: (1) open-trial pilot (2) randomized control trial. We hypothesize that I-CBT will be a feasible and acceptable treatment that will result in significant reductions in anxiety and opioid use.
Primary Outcome
Number of weeks of opioid use at Week 12 for the last 4 weeks of treatment (Weeks 9-12), as assessed by self-report and validated by urine drug screen
Conditions Studied
Interventions
- BEHAVIORAL I-CBT
- BEHAVIORAL IDC
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-12-19 |
| Phase | NA |
What the finished NCT02252068 record still lists
NCT02252068 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,140-participant average among 84 other Anxiety Disorders trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Anxiety Disorders appearing as the primary indexed condition, and to 2 interventions - of which I-CBT is the first listed.
NCT02252068 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02252068 about?
NCT02252068 is a clinical study titled "Study of Treatment for Opioid Dependence and Anxiety Disorders". Anxiety is highly prevalent among individuals with opioid dependence and confers greater risk for continued opioid use and poor treatment outcomes. However, there are currently no efficacious treatments available for co-occurring opioid dependence and anxiety. The ultimate aims of this trial are the...
What is the current status of trial NCT02252068?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2015-01. Estimated completion is 2019-12-19.
What conditions does trial NCT02252068 study?
This clinical trial studies the following conditions: Anxiety Disorders, Opiate Addiction.
What interventions are being tested in trial NCT02252068?
The interventions under investigation include: I-CBT (BEHAVIORAL), IDC (BEHAVIORAL).
Who is sponsoring clinical trial NCT02252068?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02252068 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anxiety Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02252068's enrollment target sits among peer trials
37 76th of 84 higher than 9 of 84 other Anxiety Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Anxiety Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
RECRUITING · NA
-
CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos
RECRUITING · NA
-
Initial Assessment of the Feasibility and Efficacy of a Scalable Digital CBT for Generalized Anxiety and Associated Health Behaviors in a Cardiovascular Disease Population
RECRUITING · NA
-
Managing Anxiety in Pediatric Primary Care (MAPP)
RECRUITING · NA
-
DINO RCT - Treating Anxiety in Children With Autism
RECRUITING · NA
-
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia